The user is using testosterone and finasteride to prevent hairloss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hairloss.
Hairloss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hairloss.
The user plans to stop finasteride after three months, believing hairloss isn't due to DHT, and will continue with oral minoxidil, microneedling, and ketoconazole shampoo. They suspect stress and poor nutrition are the main causes and seek opinions on DHT blockers' effectiveness.
Hairloss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
A permanent hairloss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.